Evidence map›Paper›PMID 38772920›Full record

ArticlePflugers Archiv : European journal of physiology2024

A role for sirtuin 1 in FGF23 activation following β-glycerophosphate treatment.

Danielle M A Ratsma, Max Muller, Marijke Koedam, M Carola Zillikens, Bram C J van der Eerden

Abstract read
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danielle M A RatsmaLaboratory for Calcium and Bone Metabolism and Erasmus MC Bone Centre, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Room Ee585b, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Max MullerLaboratory for Calcium and Bone Metabolism and Erasmus MC Bone Centre, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Room Ee585b, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Marijke KoedamLaboratory for Calcium and Bone Metabolism and Erasmus MC Bone Centre, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Room Ee585b, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
M Carola ZillikensLaboratory for Calcium and Bone Metabolism and Erasmus MC Bone Centre, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Room Ee585b, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Bram C J van der EerdenLaboratory for Calcium and Bone Metabolism and Erasmus MC Bone Centre, Department of Internal Medicine, Erasmus MC, Erasmus University Medical Center, Room Ee585b, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. b.vandereerden@erasmusmc.nl.

Funding

Health~Holland LSHM18029
6 · The paper itself

Abstract

Phosphate homeostasis is vital for many biological processes and disruptions in circulating levels can be detrimental. While the mechanisms behind FGF23 regulation have been regularly studied, the role of extracellular phosphate sensing and its impact on fibroblast growth factor 23 (FGF23) expression remains unclear. This study aimed to investigate the involvement of reactive oxygen species (ROS), silent information regulator 1 (SIRT1), and Hairy and Enhancer of Split-1 (HES1) in regulating FGF23 in FGF23 expressing MC3T3-E1 cells. MC3T3-E1 cells treated with β-glycerophosphate (BGP) resulted in increased Fgf23 expression. Inhibition of ROS formation by inhibition of NADPH oxidase, which is essential for ROS production, did not affect this response to BGP, suggesting ROS is not involved in this process. Moreover, treatment with tert-butyl hydroperoxide (TBHP), a ROS-inducing agent, did not increase Fgf23 expression. This suggests that ROS machinery is not involved in FGF23 stimulation as previously suggested. Nonetheless, inhibition of SIRT1 using Ex527 eliminated the Fgf23 response to BGP, indicating its involvement in FGF23 regulation after BGP treatment. Indeed, activation of SIRT1 using SRT1720 increased Fgf23 expression. Moreover, transcription factor Hes1 was upregulated by BGP treatment, which was diminished when cells were treated with Ex527 implying it is also regulated through SIRT1. These findings suggest the existence of an upstream SIRT1-HES1 axis in the regulation of FGF23 by phosphate, though we were unable to find a role for ROS in this process. Further research should provide insights into phosphate homeostasis and potential therapeutic targets for phosphate-related disorders.

Indexed as

Fibroblast Growth Factor-23Fibroblast Growth FactorsGlycerophosphatesReactive Oxygen SpeciesSirtuin 1AnimalsCarbazolesCell LineHeterocyclic Compounds, 4 or More RingsMiceTranscription Factor HES-1beta-glycerophosphoric acidCarbazolesFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsGlycerophosphatesHeterocyclic Compounds, 4 or More RingsReactive Oxygen SpeciesSirt1 protein, mouseSirtuin 1SRT1720Transcription Factor HES-1Fibroblast growth factor 23NutritionOsteocytesPhosphateReactive oxygen speciesSirtuin 1

Identifiers

PMID38772920
PMCPMC11271368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.